Anbio Biotechnology is making strides in the European healthcare sector with its flagship product, the AF-100 C, a pioneering compact fluorescent immunoassay analyzer set to transform point-of-care diagnostics. With its capacity to perform over 70 assays, the AF-100 C is designed to bolster healthcare provision within the EU, enhancing patient outcomes and care.
Anbio Biotechnology (Anbio), a global pioneer in vitro diagnostics, is thrilled to announce the debut of its diverse “Point of Care” product range in the European Union. This initiative represents a significant expansion for Anbio, facilitating new partnerships with EU distributors and healthcare providers, and showcasing the company’s commitment to delivering state-of-the-art diagnostic solutions to the European market.
Anbio, known for its innovative approach and broad product range beyond Covid testing kits, is a dynamic force in the diagnostics field. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” stated Michael Lau, Chief Executive Officer of Anbio.
A Forefront Analyzer with Extensive Testing Capabilities
At the heart of Anbio’s launch activities in the EU is the AF-100 C analyzer, an advanced, portable, rechargeable compact fluorescent Immunoassay (FIA) analyzer that is compact yet powerful. Equipped with over 70 CE marked assays for a wide range of analytes, including inflammation markers and infectious diseases, the AF-100 C is set to redefine clinical diagnostics across Europe.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau remarked. Its portability and high throughput make it an ideal choice for varied clinical environments, ensuring healthcare professionals can provide superior patient care with efficiency.
Enhancing Healthcare with Rapid, Precise Diagnostics
Anbio’s FIA test portfolio promises rapid results in 3 to 15 minutes, marking a significant advancement in diagnostic technologies. The use of RFID chip technology in reagents for enhanced accuracy and ambient temperature storage capabilities up to 24 months positions Anbio to address the immediate needs of Europe’s healthcare sector.
As Anbio Biotechnology ventures into the European market, it extends an invitation to distributors and healthcare practitioners to explore its cutting-edge diagnostic offerings. Committed to elevating patient care through affordable, precise, and dependable diagnostics, Anbio is poised to forge partnerships with healthcare entities across the EU.
